Microdeletion and microduplication syndromes Flashcards

(38 cards)

1
Q

What does microdeletion mean?

A

Microdeletion (5-10Mb) means only 1 copy of that region is left and haploinsufficiency for dosage sensitive genes results in an abnormal phenotype.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What can cause microdeletions/microduplications?

A

Caused by Nonallelic Homologous Recombination (NAHR).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the difference in phenotype severity between deletions and duplications?

A

More severe phenotype for deletions than duplications.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does reduced penetrance mean in the context of microdeletions/microduplications?

A

Microdeletions/microduplications may be inherited from an unaffected parent, demonstrating reduced penetrance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What factors influence variable expressivity and reduced penetrance?

A
  • Variable breakpoints
  • Differences in genetic background
  • Unmasking of recessive variants
  • Epigenetic modifications, imprinting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Charcot-Marie-Tooth (CMT1A) syndrome caused by?

A

CMT1A is caused by a reciprocal 1.4Mb duplication encompassing the dosage-sensitive PMP22 gene at 17p11.2.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What characterizes Charcot-Marie-Tooth (CMT1A) syndrome?

A

CMT1 is characterized by distal muscle weakness, atrophy, sensory loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is Smith-Magenis syndrome (SMS) caused by?

A

SMS is caused by recurrent 3.7Mb deletion/duplications generated by NAHR between LCRs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the characteristic features of Smith-Magenis syndrome (SMS)?

A
  • Distinctive facial features
  • Short stature
  • Developmental delay
  • Cognitive impairment
  • Behavioral abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is Williams syndrome (WS) characterized by?

A
  • Cardiovascular disease
  • Distinctive facies
  • Intellectual disability
  • Growth abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What causes Williams syndrome (WS)?

A

WS is caused by a contiguous gene deletion of the Williams-Beuren syndrome critical region (WBSCR) at 7q11.23.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is Prader-Willi syndrome (PWS) characterized by?

A
  • Hypotonia
  • Obesity
  • Developmental delay
  • Cognitive impairment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What genetic mechanisms can lead to Prader-Willi syndrome (PWS)?

A
  • Paternal deletion
  • Maternal uniparental disomy
  • Imprinting defect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What characterizes Angelman syndrome (AS)?

A
  • Severe developmental delay
  • Severe speech impairment
  • Microcephaly
  • Seizures
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is Miller-Dieker syndrome (MDS) characterized by?

A

MDS is characterized by lissencephaly, microcephaly, and severe mental retardation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the key features of Cri-du-chat syndrome?

A
  • Distinctive cat-like cry
  • Severe developmental delay
  • Microcephaly
  • Low birth weight
  • Hypotonia in infancy
  • Distinctive facial features
17
Q

What methods can be used to detect microdeletion/microduplication syndromes?

A
  • Genomic Microarrays
  • Fluorescence In Situ Hybridization
  • Quantitative Polymerase Chain Reaction
  • Multiplex Ligation-Dependent Probe Amplification
  • Optical Genome Mapping
18
Q

True or False: Optical Genome Mapping can detect triploidies.

20
Q

What are CNVs?

A

Structural variations in the genome involving changes in the number of copies of a particular genomic region, such as deletions and duplications.

21
Q

What are microarrays commonly used for?

A

Detection of idiopathic learning difficulties and established or new susceptibility regions associated with developmental delay, intellectual disabilities, and other neurodevelopmental disorders.

22
Q

What is a disadvantage of CMA?

A

Balanced rearrangements not detected.

23
Q

What might not be detected depending on the platform when using CMA?

A

Triploidy and low level mosaicism.

24
Q

What is one reason marker chromosomes might be missed?

A

Depending on the size, marker composition, and coverage of the specific chromosomal region present on the marker.

25
What type of structural information does CMA not provide?
Karyotype analysis or FISH may be required as a follow-up test.
26
What can be challenging to interpret in CMA results?
Variants of Uncertain Significance (VOUS).
27
What framework has the ACMG developed?
A quantitative, evidence-based scoring framework to evaluate CNVs.
28
What is the scoring metric for copy number losses and gains?
Separate scoring metrics are assigned to each piece of evidence.
29
What is the significance of a CNV with a final score of ≥0.99?
Considered pathogenic.
30
What do scores between -0.89 and 0.89 indicate?
Variants of uncertain significance (VUS).
31
What databases can be used for CNV interpretation?
* Ensembl * Decipher * DGV
32
What is an advantage of using arrays over traditional karyotyping techniques?
Higher resolution detection of unbalanced abnormalities.
33
What size of unbalanced abnormalities can arrays detect?
A few kb in size.
34
What can SNP arrays detect that traditional karyotyping cannot?
Mosaicism, extended regions of loss of heterozygosity, and uniparental disomy.
35
How is DNA processed in CMA compared to karyotype?
DNA is extracted from uncultured cells, allowing quicker processing.
36
What is the aim of the DDD Project?
To advance clinical genetic practice for children with developmental disorders.
37
What does the DDD Project address?
New ethical challenges raised by the application of the latest microarray and sequencing methods.
38
What will the findings of the DDD Project help design?
More efficient clinical genetic practices.